EUVIMEDEUVIMED entdecken
Open Access

Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials

Claire Gallois iD, Qian Shi iD, Levi D Pederson iD, Thierry André iD, Timothy J Iveson iD, Alberto F Sobrero iD, Steven Alberts iD, Aimery de Gramont iD, Jeffrey A Meyerhardt iD, Thomas George iD, Hans-Joachim E Schmoll iD, Ioannis Souglakos und 13 weitere

Journal of Clinical Oncology · 2024

DOI: 10.1200/jco.23.01326 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Claire Gallois und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Digestive Oncology, Georges Pompidou European Hospital, SIRIC CARPEM, Paris-Cité University, Paris, France. Hauptthemen laut MEDLINE: Oxaliplatin, Colonic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Organoplatinum Compounds. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE A number of studies suggest that older patients may have reduced or no benefit from the addition of oxaliplatin to fluoropyrimidines as adjuvant chemotherapy for stage III colon cancer (CC). MATERIALS AND METHODS We studied the prognostic impact of age, as well as treatment adherence/toxicity patterns according to age, in patients with stage III CC who received 3 or 6 months of infusional fluorouracil, leucovorin, and oxaliplatin/capecitabine and oxaliplatin (CAPOX) on the basis of data collected from trials from the ACCENT and IDEA databases. Associations between age and time to recurrence (TTR), disease-free survival (DFS), overall survival (OS), survival after recurrence (SAR), and cancer-specific survival (CSS) were assessed by a Cox model or a competing risk model, stratified by studies and adjusted for sex, performance status, T and N stage, and year of enrollment. RESULTS A total of 17,909 patients were included; 24% of patients were age older than 70 years (n = 4,340). Patients age ≥70 years had higher rates of early treatment discontinuation. Rates of grade ≥3 adverse events were similar between those older and younger than 70 years, except for diarrhea and neutropenia that were more frequent in older patients treated with CAPOX (14.2% v 11.2%; P = .01 and 12.1% v 9.6%; P = .04, respectively). In multivariable analysis, TTR was not significantly different between patients

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OxaliplatinColonic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsOrganoplatinum CompoundsNeoplasm StagingCapecitabineLeucovorinHumansAgedChemotherapy, AdjuvantFemaleMaleAge FactorsMiddle AgedFluorouracilDisease-Free SurvivalAged, 80 and over

Substanzen

OxaliplatinOrganoplatinum CompoundsCapecitabineLeucovorinFluorouracil

Autor:innen und Institutionen

  • Department of Gastroenterology and Digestive Oncology, Georges Pompidou European Hospital, SIRIC CARPEM, Paris-Cité University, Paris, France.
  • Department of Quantitative Health Science, Mayo Clinic, Rochester, MN.
  • Department of Medical Oncology, Hôpital Saint-Antoine, Sorbonne Université, Paris, France.
  • Department of Medical Oncology, University of Southampton, Southampton, United Kingdom.
  • Medical Oncology, IRCCS San Martino IST, Genoa, Italy.
  • Department of Oncology, Mayo Clinic, Rochester, MN.

ORCID-Profile: Claire Gallois, Qian Shi, Levi D Pederson, Thierry André, Timothy J Iveson, Alberto F Sobrero, Steven Alberts, Aimery de Gramont, Jeffrey A Meyerhardt, Thomas George, Hans-Joachim E Schmoll, Andrea Harkin, Frank A Sinicrope, Eiji Oki, Anthony F Shields, Ioannis Boukovinas, Sara Lonardi, Greg Yothers, Takayuki Yoshino, Richard M Goldberg, Julien Taieb, Demetris Papamichael

Förderung

  • NCI NIH HHS

Zitieren

APA

Gallois, C., Shi, Q., Pederson, L. D., André, T., Iveson, T. J., Sobrero, A. F., Alberts, S., de Gramont, A., Meyerhardt, J. A., George, T., Schmoll, H. E., Souglakos, I., Harkin, A., Labianca, R., Sinicrope, F. A., Oki, E., Shields, A. F., Boukovinas, I., Kerr, R., …, & Papamichael, D. (2024). Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.01326

Vancouver

Gallois C, Shi Q, Pederson LD, André T, Iveson TJ, Sobrero AF, et al. Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials. Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.01326

BibTeX
@article{Gallois2024,
  author = {Gallois, Claire and Shi, Qian and Pederson, Levi D and André, Thierry and Iveson, Timothy J and Sobrero, Alberto F and Alberts, Steven and de Gramont, Aimery and Meyerhardt, Jeffrey A and George, Thomas and Schmoll, Hans-Joachim E and Souglakos, Ioannis and Harkin, Andrea and Labianca, Roberto and Sinicrope, Frank A and Oki, Eiji and Shields, Anthony F and Boukovinas, Ioannis and Kerr, Rachel and Lonardi, Sara and Yothers, Greg and Yoshino, Takayuki and Goldberg, Richard M and Taieb, Julien and Papamichael, Demetris},
  title = {Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1200/jco.23.01326}
}
Kostenlos starten →